Skip to main content

Advertisement

SpringerLink
Log in

Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Introduction: We evaluated the efficacy of oral vinorelbine (OV) (Navelbine oral® Boeringer-Ingelheim Austria) in patients with advanced breast cancer as first-line therapy or after progressing under earlier line chemotherapies alone or in combination with trastuzumab (T). Patients and methods: Seventy-eight patients [median age: 63.5 years (y), range (r): 38–84 years] were included into this trial. Patients with her-2/neu positive tumours received a combination of OV and T. Treatment effect was evaluated every three cycles and treatment continued until progression. OV was administered in a dose of 60 mg/m2 on day 1 and 8, q = 21 days, and no dose escalation to 80 mg/m2 was performed. Results: We observed a complete response in 5.9% of patients, partial remission in 22.1%, stable disease (SD) > 6 months in 33.8%, SD < 6 months in 2.9%, and progression despite treatment in 35.3%, respectively. Time to progression was 6 months (range 1–23+). The main toxicities consisted of nausea/vomiting (N/V) and neutropenia. Grade IV neutropenia was found in 5 patients (6.4%), grade III in 6 patients (7.7%) and grade I and II in 11.5%. We did not find any grade IV N/V in our patients, however, grade III N/V was observed in 3.8%. No other grade III and IV toxicities were reported. Conclusion: OV appears to be effective in the treatment of advanced breast cancer at the dose and schedule chosen. It is well tolerated, effective, and the oral formulation is an advantage for the patients as well as for the nursing staff.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ligibel JA, Winer EP (2002) Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 29:38–43

    PubMed  CAS  Google Scholar 

  2. Thomssen C (2001) Trials of new combinations of Herceptin in metastatic breast cancer. Anticancer Drugs 12(Suppl. 4):S19–S25

    PubMed  Google Scholar 

  3. Vogel CL, Franco SX (2003) Clinical experience with trastuzumab (herceptin). Breast J 9:452–462

    Article  PubMed  CAS  Google Scholar 

  4. Burstein HJ, Harris LN, Marcom PK, et al (2003) Trastuzumab and vinorelbine as first-line therapy for Her2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889–2895

    Article  PubMed  CAS  Google Scholar 

  5. Winer EP, Burstein HJ (2001) New combinations with herceptin in metastatic breast cancer. Oncology 61(Suppl. 2):50–57

    Article  PubMed  CAS  Google Scholar 

  6. Jahanzeb M, Mortimer JE, Yunus F, et al (2002) Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with Her2(+) metastatic breast cancer. Oncologist 7:410–417

    Article  PubMed  CAS  Google Scholar 

  7. Montemurro F, Valabrega G, Aglietta M (2004) Trastuzumab-based combination therapy for breast-cancer. Expert Opin Pharmacother 5:81–96

    Article  PubMed  CAS  Google Scholar 

  8. Jahanzeb M (2003) Trastuzumab-based combinations in metastatic breast cancer: how to make a choice. Clin Breast Cancer 1:28–38

    Article  Google Scholar 

  9. Suzuki Y, Tokuda Y, Saito Y, et al (2003) Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol 33:514–517

    Article  PubMed  Google Scholar 

  10. Winer EP, Burstein HJ (2001) New combinations with herceptin in metastatic breast cancer. Oncology 61(Suppl. 2):50–57

    Article  PubMed  CAS  Google Scholar 

  11. Burstein HJ, Kuter I, Campos SM, et al (2004) Clinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing breast cancer. J Clin Oncol 15:2722–2730

    Google Scholar 

  12. Leveque D, Jehl F (1996) Clinical pharmacokinetics of vinorelbine. Clin Pharmacokinet 32:323

    Google Scholar 

  13. Smith GA (1995) Current status of vinorelbine for breast cancer. Oncology (Huntingt) 9:767–773

    CAS  Google Scholar 

  14. Rossi A, Gridelli C, Gebbia V, et al (2003) Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer. Anticancer Res 23:1657–1664

    PubMed  CAS  Google Scholar 

  15. Depierre A, Freyer G, Jassem J, et al (2001) Oral vinorelbine: feasibility and safety profile. Ann Oncol 12:1677–1681

    Article  PubMed  CAS  Google Scholar 

  16. Variol P, Nguyen L, Tranchand B, et al (2002) A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 58:467–476

    Article  PubMed  CAS  Google Scholar 

  17. Burstein HJ, Kuter I, Campos SM, et al (2004) Clinical activity of trastuzumab and vinorelbine in women with Her2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722–2730

    Google Scholar 

  18. Bonneterre J, Chevalier B, Focan C, et al (2001) Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). Ann Oncol 12:1683–1691

    Article  PubMed  CAS  Google Scholar 

  19. Carlson RW (1998) Quality of life issues in the treatment of metastatic breast cancer. Oncology (Huntingt) 12:27–31

    CAS  Google Scholar 

  20. Leyland-Jones B, Gelmon K, Ayoub JP, et al (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965–3971

    Article  PubMed  CAS  Google Scholar 

  21. Kaplan EL, Meier P (1958) Non parametric estimation for incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  22. O´Shaughnessy J, Miles D, Vukelja S (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823

    Article  PubMed  CAS  Google Scholar 

  23. Freyer G, Delozier T, Lichinister M, et al (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21:35–40

    PubMed  CAS  Google Scholar 

  24. Trillet-Lenoir V, Sommer H, Delozier T, et al (2004) Oral vinorelbine in metastatic breast cancer: long term results of 2 phase II studies. Eur J Cancer 2(Suppl.):Abstract 279

  25. Slamon DJ, Clark GM, Wong SG, et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  26. Boss JS, Fletcher JA, Linette GP (2003) The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307–325

    Article  PubMed  Google Scholar 

  27. Paik S, Hazan R, Fisher ER, et al (1990) Pathologic finding from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein expression in primary breast cancer. J Clin Oncol 8:103–112

    PubMed  CAS  Google Scholar 

  28. Kallioniemi OP, Holli K, Visakorpi T, et al (1991) Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 4:650–655

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, 18-20 Waehringer Guertel, Vienna, Austria

    Rupert Bartsch, Catharina Wenzel, Ursula Pluschnig, Dagmar Hussian, Ursula Sevelda, Gottfried J. Locker, Robert Mader, Christoph C. Zielinski & Guenther G. Steger

  2. Chair of Medical Oncology, Medical University of Vienna, 18-20 Waehringer Guertel, Vienna, Austria

    Christoph C. Zielinski

  3. Ludwig Boltzmann Institute for Clinical Oncology, Medical University of Vienna, 18-20 Waehringer Guertel, Vienna, Austria

    Christoph C. Zielinski

Authors
  1. Rupert Bartsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Catharina Wenzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ursula Pluschnig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dagmar Hussian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ursula Sevelda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gottfried J. Locker
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert Mader
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christoph C. Zielinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Guenther G. Steger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guenther G. Steger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartsch, R., Wenzel, C., Pluschnig, U. et al. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol 57, 554–558 (2006). https://doi.org/10.1007/s00280-005-0092-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0092-6

Keywords

Search

Navigation